Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Janux Therapeutics, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence.
3 signals not yet derived from pipeline evidence
Pipeline evidence · 1d ago
JANX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on JANX.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Janux Therapeutics, Inc. (JANX) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
Investment snapshot
JANX's AI investment thesis
Upgrade to Premium for JANX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$16.30
Market cap
$996.53M
Profitable
No
Revenue $10.27M
Net income
$-21.97M
FY Sep 1, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Janux Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Janux Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.